Press Release

 

Illumina Signs Agreement to Acquire GenoLogics, Leader in Genomics Laboratory Information Management System Market

 
 

SAN DIEGO--(BUSINESS WIRE)--Aug. 4, 2015-- Illumina, Inc. (NASDAQ:ILMN) today announced it has signed a definitive agreement to acquire GenoLogics Life Sciences Software, a developer of industry-leading laboratory information management systems (LIMS) for life sciences organizations. The acquisition strengthens Illumina’s industry leading portfolio of genetic analysis solutions.

"The acquisition of GenoLogics demonstrates Illumina's commitment to drive the adoption of sequencing in new markets and improve the genomic information workflow," said Francis deSouza, President of Illumina. "Adding GenoLogics’ products to Illumina’s portfolio is another example of our continued commitment to bring innovative sample-to-answer solutions to research and clinical labs.”

Adopted by over 120 genomic labs worldwide, GenoLogics’ Clarity LIMS™ software enables lab efficiencies and improved sample throughput with increased accuracy, fast turnaround, sample traceability, and preconfigured instrument integrations. GenoLogics has a number of current partnerships with Illumina, including the recently launched Clarity LIMS X, an edition of its industry-leading laboratory informatics platform that is optimized for use with Illumina SeqLab to address population-scale genomics workflows.

“We are excited to join Illumina and carry on the innovative spirit that GenoLogics Life Sciences Software has been known for,” said Michael Ball, CEO of GenoLogics. “Illumina and GenoLogics have had a longstanding partnership and this acquisition will enable us to widen our distribution, accelerate our product development, and provide even greater support to the Clarity LIMS community.”

GenoLogics will become part of the Illumina Enterprise Informatics business under the leadership of Sanjay Chikarmane, Senior Vice President and General Manager of Enterprise Informatics.

The impact of this transaction was contemplated in the updated 2015 financial guidance Illumina provided on July 21, 2015. The acquisition is expected to close by the end of August.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Forward-Looking Statements

This release contains forward-looking statements that involve risks and uncertainties, such as the expected closing date of the acquisition. Important factors that could cause actual results to differ materially from those in any forward-looking statements include required closing conditions and the other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Eric Endicott, 858-882-6822
pr@illumina.com